{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:39:10Z","timestamp":1790404750839,"version":"4.1.0"},"reference-count":26,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,9,16]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>No treatment demonstrated to improve survival in patients with recurrent glioblastoma (rGB) in a randomized trial. Combining axitinib with the programmed cell death ligand 1 blocking monoclonal antibody avelumab may result in synergistic activity against rGB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients with rGB following prior surgery, radiation therapy and temozolomide chemotherapy were stratified according to their baseline use of corticosteroids. Patients with a daily dose of \u22648 mg of methylprednisolone (or equivalent) initiated treatment with axitinib (5 mg oral two times per day) plus avelumab (10 mg\/kg intravenous every 2 weeks) (Cohort-1). Patients with a higher baseline corticosteroid dose initiated axitinib monotherapy; avelumab was added after 6 weeks of therapy if the corticosteroid dose could be tapered to \u22648 mg of methylprednisolone (Cohort-2). Progression-free survival at 6 months (6-m-PFS%), per immunotherapy response assessment for neuro-oncology criteria, served as the primary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between June 2017 and August 2018, 54 patients (27 per cohort) were enrolled and initiated study treatment (median age: 55 years; 63% male; 91% Eastern Cooperative Oncology Group Performance Status 0\u20131). Seventeen (63%) patients treated in Cohort-2 received at least one dose of avelumab. The 6-m-PFS% was 22.2% (95% CI 6.5% to 37.9%) and 18.5% (95% CI 3.8% to 33.2%) in Cohort-1 and Cohort-2, respectively; median overall survival was 26.6 weeks (95% CI 20.8 to 32.4) in Cohort-1 and 18.0 weeks (95% CI 12.5 to 23.5) in Cohort-2. The best objective response rate was 33.3% and 22.2% in Cohort-1 and Cohort-2, respectively, with a median duration of response of 17.9 and 19.0 weeks. The most frequent treatment-related adverse events were dysphonia (67%), lymphopenia (50%), arterial hypertension and diarrhea (both 48%). There were no grade 5 adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of avelumab plus axitinib has an acceptable toxicity profile but did not meet the prespecified threshold for activity justifying further investigation of this treatment in an unselected population of patients with rGB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-001146","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T17:45:50Z","timestamp":1602870350000},"page":"e001146","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03291314","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9535-0430","authenticated-orcid":false,"given":"Gil","family":"Awada","sequence":"first","affiliation":[{"name":"Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Ben Salama","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"De Cremer","sequence":"additional","affiliation":[{"name":"Psychology, Vrije Universiteit Brussel, Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Katharina","family":"Schwarze","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Fischbuch","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Seynaeve","sequence":"additional","affiliation":[{"name":"Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Du Four","sequence":"additional","affiliation":[{"name":"Neurosurgery, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Vanbinst","sequence":"additional","affiliation":[{"name":"Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Michotte","sequence":"additional","affiliation":[{"name":"Pathology, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Everaert","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rogiers","sequence":"additional","affiliation":[{"name":"Psychiatry, Centre Hospitalier Universitaire Brugmann, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Theuns","sequence":"additional","affiliation":[{"name":"Psychology, Vrije Universiteit Brussel, Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Duerinck","sequence":"additional","affiliation":[{"name":"Neurosurgery, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"2025100300214697000_8.2.e001146.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70025-7"},{"key":"2025100300214697000_8.2.e001146.2","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials","volume":"17","author":"Wong","year":"1999","journal-title":"J Clin Oncol"},{"key":"2025100300214697000_8.2.e001146.3","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-062"},{"key":"2025100300214697000_8.2.e001146.4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now043"},{"key":"2025100300214697000_8.2.e001146.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721"},{"key":"2025100300214697000_8.2.e001146.6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-642-01222-8_3","article-title":"Axitinib (AG-013736)","volume":"184","author":"Kelly","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"2025100300214697000_8.2.e001146.7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11060-014-1612-1","article-title":"Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma","volume":"121","author":"Lu","year":"2015","journal-title":"J Neurooncol"},{"key":"2025100300214697000_8.2.e001146.8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-016-2092-2","article-title":"Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma","volume":"128","author":"Duerinck","year":"2016","journal-title":"J Neurooncol"},{"key":"2025100300214697000_8.2.e001146.9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11060-017-2629-z","article-title":"Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma","volume":"136","author":"Duerinck","year":"2018","journal-title":"J Neurooncol"},{"key":"2025100300214697000_8.2.e001146.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2025100300214697000_8.2.e001146.11","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nox036.071","article-title":"OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143","volume":"19","author":"Reardon","year":"2017","journal-title":"Neuro Oncol"},{"key":"2025100300214697000_8.2.e001146.12","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.998107","article-title":"Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model","volume":"4","author":"Du Four","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025100300214697000_8.2.e001146.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1836-3"},{"key":"2025100300214697000_8.2.e001146.14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"2025100300214697000_8.2.e001146.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2025100300214697000_8.2.e001146.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.2464"},{"key":"2025100300214697000_8.2.e001146.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707358"},{"key":"2025100300214697000_8.2.e001146.18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.2006","article-title":"Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients","volume":"36","author":"Reardon","year":"2018","journal-title":"JCO"},{"key":"2025100300214697000_8.2.e001146.19","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou307"},{"key":"2025100300214697000_8.2.e001146.20","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862"},{"key":"2025100300214697000_8.2.e001146.21","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1461304","article-title":"Large-Scale analysis reveals the specific clinical and immune features of B7-H3 in glioma","volume":"7","author":"Zhang","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100300214697000_8.2.e001146.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.03.025"},{"key":"2025100300214697000_8.2.e001146.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3217"},{"key":"2025100300214697000_8.2.e001146.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308573"},{"key":"2025100300214697000_8.2.e001146.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"2025100300214697000_8.2.e001146.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00083-2"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:21:54Z","timestamp":1759476114000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,16]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/jitc-2020-001146"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001146","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}